Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009820 | 0.91 | RAB9A (0.52) | RAB9AKMT2ANPC1MEN1POLB | |
| SCHEMBL1010965 | 0.89 | NR1H4 (0.55) | RAB9AKMT2ANPC1MEN1NR1H4 | |
| SCHEMBL1010058 | 0.84 | NR1H4 (0.55) | RAB9AKMT2ANPC1MEN1POLB | |
| SCHEMBL1226743 | 0.83 | NR1H4 (0.54) | RAB9AKMT2ANPC1MEN1POLB | |
| SCHEMBL1009772 | 0.83 | NR1H4 (0.48) | RAB9AKMT2ANPC1MEN1NR1H4 | |
| SCHEMBL1651258 | 0.83 | RAB9A (0.52) | RAB9AKMT2ANPC1MEN1POLB | |
| SCHEMBL27634898 | 0.82 | RAB9A (0.51) | RAB9AKMT2ANPC1MEN1POLB | |
| SCHEMBL12568937 | 0.82 | RAB9A (0.51) | RAB9AKMT2ANPC1MEN1POLB | |
| SCHEMBL1010832 | 0.82 | RAB9A (0.51) | RAB9AKMT2ANPC1MEN1POLB | |
| SCHEMBL1009855 | 0.79 | PTGDR2 (0.58) | RAB9AKMT2ANPC1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1633726-B1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2011-01-05 | — | — | EP | disclosed |